Tag Archives | drug development strategy

AACR 2012 meeting: a window into potential new cancer drugs

The annual meeting of the American Association for Cancer Research (AACR), held in Chicago earlier this month, is one of the most important meetings of the year for cancer scientists, pharma/biotech drug development and new products professionals. Bill Sellers, in the AACR plenary session, described how Novartis are using the Cancer Cell Line Encyclopedia (CCLE) in […]

Continue Reading

Insights from AACR Molecular Targets Meeting

There was a lot of interesting science at the recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference in San Francisco. In particular, the poster sessions offered the opportunity to discuss pre-clinical and early drug development work, and share insights into pathways and mechanisms of action. If you are in new product development, it’s a […]

Continue Reading

AACR-NCI-EORTC Molecular Targets Meeting San Francisco

The favorite scientific meeting of Sally Church, PhD is the American Association for Cancer Research AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference that alternates each year between Europe and the United States. This year it is being held in San Francisco from November 12-16, 2011, and already AACR has announced that a lot of […]

Continue Reading

Personalized Medicine and Cancer Drug Development Strategy

Making a Difference to the Lives of Cancer Patients Sally Church has written over 900 blog posts on Pharma Strategy Blog about oncology and hematology new product development. One series of posts stands out, and that is the “Making a Difference” interviews with thought leaders and business visionaries who are making a difference to the […]

Continue Reading

New drugs will change the Prostate Cancer market

As marketing strategy consultants, it’s fascinating to watch the dynamics of a pharmaceutical market in rapid evolution. With three new therapies for prostate cancer approved last year (cabazitaxel, denosumab, sipuleucel-T) and the approval of abiraterone acetate expected this month, the prostate cancer market is a fast changing one. This is really good news for patients, […]

Continue Reading

What do cricket and cancer research have in common?

To answer that fascinating question you will have to read Sally Church’s post on Pharma Strategy Blog. Sally, a former junior England and Kent County ladies cricketer knows her sport. Since coming to America she has embraced NFL football, and is an avid fantasy player. Sally discusses the current cricket world cup, and whether playing […]

Continue Reading